From Vaccines to Devices — Why Materiovigilance Is a Parallel Discipline

Vaccine pharmacovigilance, covered in this module’s first six lessons, is one way pharmacovigilance extends beyond the conventional drug case this course has used as its default example. Materiovigilance — the post-market surveillance and reporting discipline specifically for medical devices — is another, and it’s worth understanding as a genuinely parallel discipline rather than a footnote to drug safety, which is exactly why CITI Program’s foundational pharmacovigilance course, a direct precedent for this module’s structure, closes with dedicated materiovigilance content rather than treating it as an aside.

The structural purpose is the same as everything this course has built: detect, assess, understand, and prevent harm from a medical product in real-world use, at scale, across the product’s entire post-market life. What changes fundamentally is the mechanics of what an investigation actually has to establish. A drug’s risk profile is largely a property of the molecule itself, characterised through trials and then monitored; a device’s risk profile often depends heavily on the specific context of its use — how it was implanted, how it was maintained, whether it was used within its intended parameters — in ways a conventional drug’s risk profile generally doesn’t.

That difference shapes device incident investigation directly. When a pacemaker malfunctions, a defibrillator fails to deliver a shock, or a surgical mesh causes complications, the investigation has to distinguish between at least three genuinely different root causes before any meaningful response is possible: a manufacturing or design defect (the device itself was flawed), a use error (implanted or maintained incorrectly — echoing the immunization-error category from Lesson 14.2), or expected end-of-life degradation (the device performed exactly as specified, and simply reached the end of its designed service life). Each of those three root causes triggers a completely different corrective response — a manufacturing defect triggers a recall and CAPA at the production level; a use error triggers training and procedural correction; expected degradation triggers nothing beyond routine device replacement scheduling.

This module works through materiovigilance in the same structural order the vaccine section used: how devices are classified by risk (Lesson 14.8, since classification determines everything downstream, just as seriousness classification does for drug events), how incidents actually get reported (Lesson 14.9), and where device and drug vigilance genuinely converge in combination products (Lesson 14.10) — building the same kind of specific, standard-curriculum fluency in device safety that the earlier lessons built for vaccine safety.